全文获取类型
收费全文 | 9731篇 |
免费 | 740篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 119篇 |
妇产科学 | 319篇 |
基础医学 | 644篇 |
口腔科学 | 362篇 |
临床医学 | 1189篇 |
内科学 | 1957篇 |
皮肤病学 | 119篇 |
神经病学 | 263篇 |
特种医学 | 391篇 |
外国民族医学 | 1篇 |
外科学 | 2076篇 |
综合类 | 787篇 |
预防医学 | 1314篇 |
眼科学 | 219篇 |
药学 | 524篇 |
中国医学 | 61篇 |
肿瘤学 | 149篇 |
出版年
2024年 | 17篇 |
2023年 | 187篇 |
2022年 | 353篇 |
2021年 | 522篇 |
2020年 | 519篇 |
2019年 | 492篇 |
2018年 | 492篇 |
2017年 | 392篇 |
2016年 | 378篇 |
2015年 | 379篇 |
2014年 | 833篇 |
2013年 | 799篇 |
2012年 | 489篇 |
2011年 | 591篇 |
2010年 | 494篇 |
2009年 | 450篇 |
2008年 | 423篇 |
2007年 | 400篇 |
2006年 | 352篇 |
2005年 | 288篇 |
2004年 | 292篇 |
2003年 | 233篇 |
2002年 | 169篇 |
2001年 | 124篇 |
2000年 | 127篇 |
1999年 | 96篇 |
1998年 | 77篇 |
1997年 | 71篇 |
1996年 | 75篇 |
1995年 | 63篇 |
1994年 | 65篇 |
1993年 | 41篇 |
1992年 | 38篇 |
1991年 | 28篇 |
1990年 | 27篇 |
1989年 | 33篇 |
1988年 | 21篇 |
1987年 | 26篇 |
1986年 | 12篇 |
1985年 | 18篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1976年 | 5篇 |
1973年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Mohammad Sotoudeh Shila Jalali Shunichi Usami John Y-J. Shyy Shu Chien 《Annals of biomedical engineering》1998,26(2):181-189
The objective of this study is to design a new apparatus to allow the control of the magnitude and frequency of dynamic stretch applied uniformly to cells cultured on a silicon elastic membrane. The apparatus is designed to produce equi-biaxial dynamic stretches with area changes ranging from 0% to 55% and frequencies ranging from 0 to 2 Hz. Homogeneous finite strain analysis using triangles of markers was performed to compute the symmetric two-dimensional Lagrangian strain tensor on the membrane. Measurements of strain in both static and dynamic conditions showed that the shear component of the strain tensor (Erc) was near zero, and that there was no significant difference between radial (Err) and circumferential (Ecc) components, indicating the attainment of equi-biaxial strain. Bovine aortic endothelial cells were transiently transfected with a chimeric construct in which the luciferase reporter is driven by TPA-responsive elements (TRE). The transfected cells cultured on the membrane were stretched. The luciferase activity increased significantly only when the cells were stretched by 15% or more in area. Cells in different locations of the membrane showed similar induction of luciferase activities, confirming that strain is uniform and equi-biaxial across the membrane. © 1998 Biomedical Engineering Society.
PAC98: 8780+s, 8745-k, 8722-q 相似文献
12.
Takeshi Komoda MD Thorsten Drews MD Hans B. Lehmkuhl MD Roland Hetzer MD PhD 《Journal of artificial organs》2006,9(1):29-33
The Eurotransplant (ET) allocation algorithm, newly implemented in 2000, gives priority for heart transplantation (HTx) to
patients with high urgency (HU) status, but now this status is rescinded upon ventricular assist device (VAD) implantation
and only regained if severe complications occur during mechanical circulatory support (MCS). We studied the effects of this
change on the patients in our institute who were waiting for HTx with MCS. The median duration of MCS until HTx in adult patients
gradually increased from 3.1 months in 1994, reaching a peak of 16.7 months in 2000, and then gradually decreased to 6.0 months
in 2003. Among the patients with VAD implantation as a bridge to HTx, two patients were on MCS for more than 1 year (the longest
duration of MCS being 1.6 years) at the end of 1999, and this figure increased to nine patients and a maximum MCS duration
of 3.7 years at the end of 2003. These data imply that the patients in whom a complication occurred in the early phase of
MCS and who had overcome this complication underwent HTx early with HU status, and those who were stable during MCS waited
a long time for HTx. Furthermore, the number of patients in the latter group is increasing. The new allocation algorithm imposes
on patients with MCS waiting for HTx who are relatively young and free from complications and serious coexisting disease,
very long-term MCS without an end to VAD bridging, which is almost equivalent to destination therapy.
Part of this paper was presented at the 42nd JSAO Conference (Tokyo, October 5–7, 2004) 相似文献
13.
Simulation study of the Hemopump as a cardiac assist device 总被引:2,自引:0,他引:2
A dynamic model was developed for a Hemopump that withdraws blood from the left ventricle and discharges it to the aorta through
a miniature axial-flow pump. Incorporation of the Hemopump model in a previously established model for the canine circulatory
system enabled the effects of the Hemopump on various haemodynamic variables of the circulatory system to be studied, and
the benefit of the Hemopump to the failing heart was investigated. In addition, the influence of the physiological status
of the right ventricle on the Hemopump performances was examined, and the synchronous and non-synchronous operations of the
Hemopump were compared. Results verified that the Hemopump assists the failing heart by increasing the oxygen supply, while
reducing the oxygen consumption of the heart through a reduction in the workload of the left ventricle. These beneficial effects
were enhanced when the pump's rotation speed was increased. When pump speed was increased from 17000 to 23000 revolutions
min−1, the oxygen supply increased 101%, and the oxygen consumption decreased 60%. However, when the pump rotation speed was too
high, the inflow to the pump could be impaired and the pump performance could be negatively affected. Predications from the
model were in good agreement with the results previously obtained in animal experiments and in vitro measurements. 相似文献
14.
Motonobu Nishimura MD Takashi Nishimura MD Masayuki Ishikawa MD Ayumu Masuoka MD Nobuyuki Okamura MD Keiko Abe MD Takahiro Matsuoka MD Mika Iwazaki MD Kazuhito Imanaka MD Haruhiko Asano MD Shunei Kyo MD 《Journal of artificial organs》2006,9(4):209-213
The presence of a significant organ dysfunction does not immediately exclude patients from consideration for treatment with
a left ventricular assist system (LVAS). However, in treating morbid circulatory shock patients with multiple organ failure,
it is important to know the preoperative and postoperative factor or factors related to the recovery of the damaged organ
function. In this study, we retrospectively analyzed patients receiving a LVAS at our institution and tried to determine the
important factors related to the survival of patients with multisystem failure. Twenty-seven patients who underwent LVAS placement
at Saitama Medical School Hospital between 1993 and 2003 were included in this study. The preoperative risk factors analyzed
were renal dysfunction, respiratory dysfunction, hepatic dysfunction, the existence of active infection, and the combination
of all four factors. As a postoperative factor, the pump flow index (mean LVAS pump flow during the first 2 weeks after LVAS
surgery divided by the body surface area) was analyzed. None of the analyzed preoperative factors could predict survival after
LVAS surgery, but a pump flow index of less than 2.5 l/min/m2 had a significant relationship with death after LVAS surgery. Further analysis revealed that all the patients with a pump
flow index of 3.0 l/min/m2 or more could overcome preoperative organ dysfunction. Congestive heart failure patients with multisystem failure need luxury
pump flow for successful LVAS surgery; this factor could be especially important in device selection and postoperative management. 相似文献
15.
Motokazu Hori 《Artificial organs》1986,10(3):211-213
Early in 1956, the first model of a biological artificial liver, using a live dog's liver incorporated in a cross-hemodialyzer, was placed in an experimental animal with portocaval encephalopathy. This "biological artificial liver," a hybrid artificial liver in the present terminology, was the first in the world. In October 1958, the first human patient, a young male patient in hepatic coma due to liver cirrhosis, was placed on the laboratory-made biological artificial liver composed of four parabiotic cross-hemodialyzers connected with four live dogs' livers to which the "hepatic reactors" for ammonium adsorption and acid-base balance were additionally equipped. This first case was very successful, resulting in the patient's recovery from coma. This article introduces the past history of the artificial liver, research of which has mainly been conducted in Japan since the early 1950s by the author, M. Mito, and Y. Nosé. Until recently, little progress has been made in this field through the application of blood purification principles such as hemoadsorption, plasmapheresis, and other modifications and combinations. Accumulation of clinical experiences with such conventional methods has stimulated the third generation of the artificial liver to a return to a hybrid organ applying modern science and technology. A concept of hybrid organs in comparison with organ transplants is introduced. The Japanese national project of developing a new artificial liver system, as conducted by the author as the chairman and his associates, is introduced. 相似文献
16.
讨论了基于HART协议智能设备的实时管理系统,介绍了HART协议的基本规范,以及如何利用已有集散控制系统(DCS)和工厂信息网络的集成实现实时信息共享,取得了良好的实际效果。 相似文献
17.
Harma K. Turbendian Jeremy Gebhardt Peter Scherkenbach Matthew J. Zawadzki Michael Shillingford 《Artificial organs》2021,45(1):55-62
Extracorporeal life support (ECLS) is an essential component of a modern congenital cardiac surgery program. The circuit components and bedside management team may, however, vary among institutions. Here, we evaluate our initial experience with a modified ventricular assist device—based ECLS circuit primarily managed by the bedside nurse. We hypothesize that our outcomes are comparable to Extracorporeal Life Support Organization (ELSO) registry data. All patients who received ECLS from January 1, 2016 to December 31, 2019 at a single institution were included. Primary outcomes were survival to ECLS decannulation and discharge or transfer. Secondary outcomes included complications from ECLS. Data were compared to available ELSO registry data. Thirty‐seven patients underwent 44 ECLS runs during the study period. Forty percent of patients had single ventricle physiology. Nearly 46% of patients received ECLS as part of extracorporeal cardiopulmonary resuscitation (eCPR). Survival to ECLS decannulation (68.2%) and survival to discharge or transfer (61.4%) did not differ from overall ELSO outcomes (69.7%, P = .870 and 50.7%, P = .136), as well as survival to discharge or transfer in a comparable cohort of ELSO centers (53.1%, P = .081). Patients with complications had a lower rate of survival to discharge or transfer but this did not reach statistical significance (47.7% vs. 75.0%, P = .455). Neurologic (50.0%), hemorrhagic (45.5%), and renal complications (31.8%) were most common in this cohort. A modified ventricular assist device‐based ECLS circuit with primary management by the bedside nurse can provide comparable support in a neonatal and pediatric cardiac surgery population. Cost analyses and further delineation of the complication profile are necessary for a complete characterization of this system. 相似文献
18.
Leon Jonker Lucy Bell Maureen Monda James Murray Matt Dawson 《Indian Journal of Orthopaedics》2021,55(4):967
PurposeAssessing surgical accuracy and patient-recorded outcome measures for patients fitted with either the OPTY-LINE intramedullary realignment system or the Tomofix plate for medial opening wedge high tibial osteotomy (HTO).Patients and methodsTwo matched case series of patients with symptomatic medial compartment osteoarthritis without other significant knee pathology. One group comprised of 19 patients receiving the Tomofix plate, whereas another comprised of 12 patients receiving the OPTY-LINE intramedullary nail. Patella-centred long leg alignment radiographs were assessed to calculate surgical accuracy in all cases. Patients completed knee injury osteoarthritis outcome scores (KOOS) and osteotomy surgery patient satisfaction questionnaires pre-operatively and at 24 months post-surgery.ResultsAbsolute surgical accuracy at 2 years post-surgery was a mean 4.2 [standard deviation 3.7] for OPTY-LINE versus 9.2 [SD 7.8] for Tomofix (p = 0.11, Mann–Whitney U test). On average, patients in either the OPTY-LINE or Tomofix cohort reported at least a minimal perceptible clinical improvement—minimum average improvement of 15—for all five KOOS themes. No significant difference in change of KOOS scores over time or patient satisfaction levels were observed between the two cohorts.ConclusionThe OPTY-LINE device for HTO performs to a similar level as the Tomofix device. Surgical accuracy data are promising for OPTY-LINE, but does not seem to readily translate into difference in patient-reported outcomes compared to Tomofix. Even longer follow-up periods, to measure survival rates, and true randomised trials on larger samples can elucidate if there is a benefit for using one device over the other. 相似文献
19.
20.
IntroductionAbdominal surgery uses various energy devices for vessel sealing, tissue dissection, and detachment. Currently, Acrosurg Revo® (Nikkiso Co., Ltd., Tokyo, Japan), a novel energy device using microwaves, has been developed for use in laparoscopic surgery. This report describes the early clinical experience of using this device in two cases of laparoscopic surgery.Presentation of caseCase 1 was of a 64-year-old woman who underwent laparoscopic abdominal incisional hernia repair. Case 2 was of a 56-year-old man with a diagnosis of ascending and sigmoid colon cancer who underwent laparoscopic right hemicolectomy and sigmoid colectomy with D3 dissection. Each surgery was completed using Acrosurg Revo® and an endoscopic electrosurgical unit. The postoperative course was uneventful, and both patients were discharged from the hospital without any complications.DiscussionWith this new and novel device, vessel sealing, hemostasis, coagulation, tissue dissection, and detachment were all possible. Notably, there was no spark or mist that hindered the surgical field of view. Furthermore, because microwave coagulation did not result in tissue carbonization, there was a considerable decrease in device tip contamination.ConclusionThe Acrosurg Revo® may be a useful energy device for laparoscopic surgery. 相似文献